Bioventix PLC (LON:BVXP - Get Free Report) passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 3,915.37 ($48.18) and traded as low as GBX 3,200 ($39.37). Bioventix shares last traded at GBX 3,350 ($41.22), with a volume of 387 shares changing hands.
Bioventix Trading Up 0.6 %
The stock has a market cap of £173.30 million, a P/E ratio of 2,036.81 and a beta of 0.35. The firm has a 50-day simple moving average of GBX 3,558.93 and a two-hundred day simple moving average of GBX 3,911.41.
Bioventix Increases Dividend
The firm also recently declared a dividend, which was paid on Thursday, November 21st. Investors of record on Thursday, November 7th were given a dividend of GBX 87 ($1.07) per share. This represents a yield of 2.4%. This is a positive change from Bioventix's previous dividend of $68.00. The ex-dividend date of this dividend was Thursday, November 7th. Bioventix's dividend payout ratio (DPR) is currently 9,693.25%.
Insiders Place Their Bets
In related news, insider Bruce Hiscock bought 24 shares of Bioventix stock in a transaction dated Friday, November 22nd. The shares were bought at an average cost of GBX 3,822 ($47.03) per share, with a total value of £917.28 ($1,128.68). Insiders acquired 385 shares of company stock worth $1,107,381 in the last quarter. 8.02% of the stock is currently owned by corporate insiders.
About Bioventix
(
Get Free Report)
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.
See Also
Before you consider Bioventix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventix wasn't on the list.
While Bioventix currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
